top of page
deliverysystem_vignette.jpg

Groundbreaking innovation

The SpyGlass Pharma™ Drug Delivery Platform combines safe, lasting treatment with the world's most common, routine ophthalmic surgery.

Spyglass Platform Pipeline

spyglass_pharma_pipeline.jpg
texture_bg.jpg

SpyGlass Pharma™ Completes Enrollment in Phase I/II Study of its Promising Long-Term Drug Delivery Platform for Glaucoma and Ocular Hypertension

ALISO VIEJO, Calif., November 19, 2024 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, today announced completion of enrollment in its Phase I/II, randomized, multi-center, controlled clinical trial (NCT06120842) evaluating SpyGlass’ Drug Delivery Platform in patients with glaucoma or ocular hypertension. The SpyGlass platform is designed to deliver multiple years of bimatoprost to lower intraocular pressure (IOP) and is implanted during routine cataract surgery. (View full press release)

Spyglass Pharma Logo - Long - Black_edited.png

Tel: 949-284-6904

27061 Aliso Creek Rd, Suite 100
Aliso Viejo, CA 92656

SUBSCRIBE

Sign up to receive SpyGlass Pharma™ news and updates.

Thanks for submitting!

© 2024 SpyGlass Pharma™. All Rights Reserved.

Follow us on LinkedIn

  • LinkedIn
bottom of page